For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2024-11-30 |
|---|---|---|---|---|
| Revenue | 0 | 174,000 | 174,000 | 183,923 |
| Cost of goods sold | 0 | 0 | 0 | 2,720 |
| Gross profit | 0 | 174,000 | 174,000 | 181,203 |
| Research and development | 671,340 | 1,784,018 | 2,717,501 | 1,953,220 |
| General and administrative | 902,291 | 1,109,786.5 | 1,206,920 | 918,690 |
| Total operating expenses | 1,573,631 | 2,893,804.5 | 3,924,421 | 2,871,910 |
| Loss from operations | -1,573,631 | -2,719,804.5 | -3,750,421 | -2,690,707 |
| Interest income | 12 | 1,408 | 190 | 11 |
| Unrealized loss on marketable securities | -22,093 | 1,754.667 | -40,375 | -15,932 |
| Total other income (loss) | -22,081 | 3,162.667 | -40,185 | - |
| Net loss before income taxes | -1,595,712 | - | - | - |
| Other nonoperating income (expense) | - | - | - | -15,921 |
| Income taxes | 1,791 | - | - | - |
| Net loss | -1,597,503 | -2,707,100 | -3,790,606 | -2,706,628 |
| Less net loss attributable to non-controlling interest | -2,496 | -2,575 | -1,514 | -2,929 |
| Net loss attributable to lexaria shareholders | -1,595,007 | -2,704,525 | -3,789,092 | -2,703,699 |
| Foreign currency translation adjustment | -5,744 | -42,258.5 | 37,173 | -3,175 |
| Total comprehensive loss | -1,600,751 | -2,746,783.5 | -3,751,919 | -2,706,874 |
| - basic and diluted | 21,376,029 | -8,484,053.5 | 18,298,309 | 16,668,513 |
| Basic and diluted loss per share | -0.07 | -0.145 | -0.21 | -0.16 |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)